dalteparin has been researched along with Coronary Stenosis in 9 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " Bleeding complications can be minimized by avoiding cross-over from UFH to enoxaparin or vice versa, or by reducing the dosage of enoxaparin." | 2.44 | Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. ( Schmidt-Lucke, C; Schultheiss, HP, 2007) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Chan, MY | 1 |
| Mahaffey, KW | 1 |
| Sun, LJ | 1 |
| Pieper, KS | 1 |
| White, HD | 1 |
| Aylward, PE | 1 |
| Ferguson, JJ | 1 |
| Califf, RM | 1 |
| Roe, MT | 1 |
| Choussat, R | 1 |
| Montalescot, G | 1 |
| Collet, JP | 1 |
| Vicaut, E | 1 |
| Ankri, A | 1 |
| Gallois, V | 1 |
| Drobinski, G | 1 |
| Sotirov, I | 1 |
| Thomas, D | 1 |
| Smith, LA | 1 |
| Harkness, M | 1 |
| Chisholm, RJ | 1 |
| Cantor, W | 1 |
| Cantor, WJ | 1 |
| Burnstein, J | 1 |
| Choi, R | 1 |
| Heffernan, M | 1 |
| Dzavik, V | 1 |
| Lazzam, C | 1 |
| Duic, M | 1 |
| Fitchett, D | 1 |
| Tan, M | 1 |
| Wawrzyniak, J | 1 |
| Kassam, S | 1 |
| Dhingra, S | 1 |
| Morrison, LJ | 1 |
| Langer, A | 1 |
| Goodman, SG | 1 |
| Schmidt-Lucke, C | 1 |
| Schultheiss, HP | 1 |
| Tramuta, DA | 1 |
| Kereiakes, DJ | 1 |
| Dippel, EJ | 1 |
| Lengerich, R | 1 |
| Broderick, TM | 1 |
| Abbottsmith, CW | 1 |
| Whang, DD | 1 |
| Roth, EM | 1 |
| Schneider, JF | 1 |
| Howard, W | 1 |
| Shimshak, TM | 1 |
| Stepinska, J | 1 |
| Banaszewski, M | 1 |
| Konopka, A | 1 |
| Szajewski, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Coronary Stenosis
| Article | Year |
|---|---|
Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome.
Topics: Acute Disease; Anticoagulants; Clinical Trials as Topic; Coronary Stenosis; Electrocardiography; Eno | 2007 |
2 trials available for dalteparin and Coronary Stenosis
| Article | Year |
|---|---|
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; | 2008 |
Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coronary Angiogra | 2006 |
6 other studies available for dalteparin and Coronary Stenosis
| Article | Year |
|---|---|
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation | 2002 |
A case of two adverse reactions.
Topics: Aged; Anaphylaxis; Angina Pectoris; Angioedema; Anticoagulants; Coronary Stenosis; Drug Interactions | 2004 |
Failure of enoxaparin during coronary stenting: a case report.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Corona | 2005 |
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; | 2000 |
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Hu | 2002 |